Digi Expands IoT Solutions for Medical, Smart Energy and Industrial Sectors with Newest Addition to the MP1 Family of System-On-Modules
13.3.2023 11:00:00 EET | Business Wire | Press release
Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) solutions, connectivity products and services, and an ST Authorized Partner, today unveiled Digi ConnectCore® MP13, the newest member of its Digi ConnectCore® MP1 family of system-on-modules (SOMs) designed for longevity, scalability and demanding product lifecycles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005132/en/
Digi ConnectCore MP13 System-on-Module unveiled at Embedded World 2023 (Graphic: Business Wire)
A compact, wireless and secure system-on-module based on the STMicroelectronics STM32MP133C MPU, Digi ConnectCore MP13 is among the industry’s smallest SOMs with pre-certified Wi-Fi 5 and Bluetooth® 5.2. This solution delivers cost-effective, flexible and reliable connectivity for original equipment manufacturers (OEMs) looking to reduce risk and product development efforts, while accelerating overall time to market of applications for the medical, smart energy and industrial sectors.
Complete with embedded security framework, Digi TrustFence®, and Digi Embedded Yocto Linux® software support, Digi ConnectCore MP13 SOMs eliminate implementation barriers and offer exceptional design flexibility for both complex and simple applications thanks to the unique and compact Digi SMTplus® surface-mount form factor (29x29 mm) — making them ideal for medical devices, industrial gateways, environmental test equipment, renewable-energy controllers and EV charging stations.
“We are delighted to expand the Digi ConnectCore MP1 family of SOMs and continue our commitment to providing off-the-shelf, wireless-enabled solutions suitable for a broad range of applications,” said Andreas Burghart, Senior Product Manager at Digi. “Designed for longevity, scalability and demanding 10+ year product lifecycles, Digi ConnectCore MP13 is a well-suited addition to our complete ecosystem of hardware, software and services that help manufacturers successfully develop and maintain connected products.”
Digi ConnectCore MP1 SOMs are distinct from other SOMs in that they offer comprehensive, fully-integrated solutions, which include a range of development tools, design support, wireless connectivity options, software and security features. These solutions include access to Digi ConnectCore Cloud Services and Digi ConnectCore Security Services, which aid in streamlining deployment, device management and ongoing maintenance across the product's entire lifecycle.
Digi ConnectCore MP13 Features
- STM32MP13x, single Cortex-A7 @ 650 MHz
- Pre-certified Wi-Fi 5 802.11a/b/g/n/ac + Bluetooth 5.2 (including DLE) option
- Up to 1 GB SLC NAND flash, up to 1 GB DDR3
- Unique ultra-low power and wake-up state management
- Dual 10/100/1000 Ethernet connectivity
- Fully validated embedded Linux software platform (Digi Embedded Yocto)
- Digi TrustFence® embedded security framework — ready-to-use security features
- Off-the-shelf development board and low-cost gateway reference design
- Industrial reliability and operating temperature with leading hardware warranty
“With the launch of Digi ConnectCore MP13, Digi has created pin-compatible family of SOMs to support the ST Microelectronics STM32MP1 microprocessors,” said Dan Kobylarz, Senior Director of Engineering, OEM Solutions Group at Digi. “The ConnectCore MP13 is ideal for the rapid development of cost-effective gateways for Smart City and Energy applications, while the ConnectCore MP15 supports connected devices with HMI requirements. With the ConnectCore MP1 SOM family, a customer gets the best of both worlds.”
For more information, visit https://www.digi.com/products/embedded-systems/digi-connectcore/system-on-modules/digi-connectcore-mp1.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit https://www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005132/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom